Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
NICE
Pharma
NICE again rejects Alzheimer's drugs from Lilly and Biogen/Eisai
After reviewing additional clinical data, England's NICE has slapped down Eli Lilly's Kisunla and Biogen and Eisai's Leqembi for a second time.
Kevin Dunleavy
Mar 6, 2025 10:47am
NICE says AZ, Daiichi failed to propose fair price on Enhertu
Nov 19, 2024 11:08am
England's NICE not sold on Lilly's Kisunla despite UK approval
Oct 23, 2024 11:00am
NHS England proposes phased rollout for Lilly's obesity med
Oct 3, 2024 3:22pm
Eisai, Biogen's Leqembi nabs UK nod but not reimbursement
Aug 22, 2024 9:23am
NICE signs off on Vertex, CRISPR's Casgevy for beta thalassemia
Aug 7, 2024 8:20pm
